全球新型药物递送系统市场规模、份额、趋势和成长分析报告（2026-2034年）

预计用于癌症治疗的新型药物输送系统的市场规模将从 2025 年的 270.7 亿美元增长到 2034 年的 1748 亿美元，2026 年至 2034 年的复合年增长率为 23.03%。

随着对高效标靶癌症治疗的需求持续成长，肿瘤领域新型药物传递系统市场正经历强劲成长。这些先进的药物传递系统旨在提高抗癌药物的生物利用度和治疗效果，同时最大限度地减少副作用。癌症患者数量的不断增加以及对个人化医疗日益增长的关注，正在推动奈米颗粒、脂质体和胶束等创新药物递送技术的发展。随着研究人员和製药公司将癌症治疗的进步作为优先事项，新型药物递送系统的市场预计将会扩大。

技术进步在塑造肿瘤治疗领域新型药物递送系统的未来中发挥关键作用。製剂技术和标靶化策略的创新提高了药物传递的精准度，实现了肿瘤局部治疗，同时保护了健康组织。此外，刺激反应系统和即时监测等智慧技术的整合，也提高了癌症治疗的疗效和安全性。随着製造商持续加大研发投入，预计新型药物递送系统在各种癌症治疗方法的应用将持续扩展。

此外，产学合作的加强正在影响癌症治疗领域新型药物递送系统的市场。随着研究人员和製药公司携手开发和检验新的递送技术，创新步伐预计将会加快。这一趋势正在推动建立伙伴关係关係，将研究成果转化为临床应用。随着市场的不断发展，技术整合、合作以及以患者为中心的理念将是成功的关键。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球新型药物递送系统市场（癌症治疗领域）产品分类

• 市场分析、洞察与预测
• 奈米颗粒（脂质体、聚合物、胶束和其他奈米颗粒）
• 栓塞颗粒（聚乙烯醇颗粒、药物释放型微球、液态栓塞剂、其他栓塞颗粒）

5. 全球癌症治疗新型药物递送系统市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第六章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第七章 公司简介

• 主要公司的市占率分析
• 公司简介
  • Teva Pharmaceutical Industries Ltd
  • Johnson & Johnson Services Inc
  • Galen
  • Merrimack Pharmaceuticals Inc
  • Shire
  • Samyang Biopharmaceuticals Corporation
  • Celgene Corporation
  • Spectrum Pharmaceuticals Inc
  • Other Market Players

The Novel Drug Delivery Systems in Cancer Therapy Market size is expected to reach USD 174.80 Billion in 2034 from USD 27.07 Billion (2025) growing at a CAGR of 23.03% during 2026-2034.

The Novel Drug Delivery Systems in Cancer Therapy Market is experiencing robust growth as the demand for effective and targeted cancer treatments continues to rise. These advanced drug delivery systems are designed to improve the bioavailability and therapeutic efficacy of anticancer agents while minimizing side effects. The increasing prevalence of cancer and the growing focus on personalized medicine are driving the development of innovative drug delivery technologies, such as nanoparticles, liposomes, and micelles. As researchers and pharmaceutical companies prioritize the advancement of cancer therapies, the market for novel drug delivery systems is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the novel drug delivery systems in cancer therapy market. Innovations in formulation technologies and targeting strategies are enhancing the precision of drug delivery, allowing for localized treatment of tumors while sparing healthy tissues. Additionally, the integration of smart technologies, such as stimuli-responsive systems and real-time monitoring, is improving the effectiveness and safety of cancer therapies. As manufacturers continue to invest in research and development, the market is likely to see increased adoption of novel drug delivery systems across various cancer treatment modalities.

Moreover, the growing emphasis on collaboration between academia and industry is influencing the novel drug delivery systems in cancer therapy market. As researchers and pharmaceutical companies work together to develop and validate new delivery technologies, the pace of innovation is expected to accelerate. This trend is driving the establishment of partnerships and collaborations that facilitate the translation of research findings into clinical applications. As the market continues to evolve, the integration of technology, collaboration, and patient-centric approaches will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Nanoparticles (Liposomes, Polymer, Micelles, Other nanoparticles)
• Embolization particles (PVA particles, Drug-eluting beads, Liquid emboli, Other Embolization particles)

COMPANIES PROFILED

• Teva Pharmaceutical Industries Ltd, Johnson Johnson Services Inc, Galen, Merrimack Pharmaceuticals Inc, Shire, Samyang Biopharmaceuticals Corporation, Celgene Corporation, Spectrum Pharmaceuticals Inc, Other market players

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Nanoparticles (Liposomes, Polymer, Micelles, Other nanoparticles) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Embolization particles (PVA particles, Drug-eluting beads, Liquid emboli, Other Embolization particles) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 5.1. Regional Outlook
• 5.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 5.2.1 By Product
  • 5.2.2 United States
  • 5.2.3 Canada
  • 5.2.4 Mexico
• 5.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 5.3.1 By Product
  • 5.3.2 United Kingdom
  • 5.3.3 France
  • 5.3.4 Germany
  • 5.3.5 Italy
  • 5.3.6 Russia
  • 5.3.7 Rest Of Europe
• 5.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 5.4.1 By Product
  • 5.4.2 India
  • 5.4.3 Japan
  • 5.4.4 South Korea
  • 5.4.5 Australia
  • 5.4.6 South East Asia
  • 5.4.7 Rest Of Asia Pacific
• 5.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 5.5.1 By Product
  • 5.5.2 Brazil
  • 5.5.3 Argentina
  • 5.5.4 Peru
  • 5.5.5 Chile
  • 5.5.6 South East Asia
  • 5.5.7 Rest of Latin America
• 5.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 5.6.1 By Product
  • 5.6.2 Saudi Arabia
  • 5.6.3 UAE
  • 5.6.4 Israel
  • 5.6.5 South Africa
  • 5.6.6 Rest of the Middle East And Africa

Chapter 6. COMPETITIVE LANDSCAPE

• 6.1. Recent Developments
• 6.2. Company Categorization
• 6.3. Supply Chain & Channel Partners (based on availability)
• 6.4. Market Share & Positioning Analysis (based on availability)
• 6.5. Vendor Landscape (based on availability)
• 6.6. Strategy Mapping

Chapter 7. COMPANY PROFILES OF GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY INDUSTRY

• 7.1. Top Companies Market Share Analysis
• 7.2. Company Profiles
  • 7.2.1 Teva Pharmaceutical Industries Ltd
  • 7.2.2 Johnson & Johnson Services Inc
  • 7.2.3 Galen
  • 7.2.4 Merrimack Pharmaceuticals Inc
  • 7.2.5 Shire
  • 7.2.6 Samyang Biopharmaceuticals Corporation
  • 7.2.7 Celgene Corporation
  • 7.2.8 Spectrum Pharmaceuticals Inc
  • 7.2.9 Other Market Players